BridgeMD
New treatment option for Hidradenitis Suppurativa (HS)
Official title Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
ClinicalTrials.gov ID: NCT06855498
What this study is testing
What is povorcitinib?
povorcitinib is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for hidradenitis suppurativa (hs).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Ability to comprehend and willingness to sign a written ICF for the study.
- Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or side effects concerns, per...
- Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
- Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
- Willingness to avoid pregnancy or fathering children as defined in the protocol.
You likely can't join if
- Had been permanently discontinued from study treatment during the parent study.
- Had temporary study drug interruption due to safety and/or how well it works reasons at or after the final visit of the parent study.
- Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:
- Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
- Live, attenuated vaccine.
- Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.
See the full eligibility criteria
- Ability to comprehend and willingness to sign a written ICF for the study.
- Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or side effects concerns, per investigator's assessment.
- Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
- Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
- Willingness to avoid pregnancy or fathering children as defined in the protocol.
- Willingness and ability to comply with the study Protocol and procedures.
- Had been permanently discontinued from study treatment during the parent study.
- Had temporary study drug interruption due to safety and/or how well it works reasons at or after the final visit of the parent study.
- Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:
- Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
- Live, attenuated vaccine.
- Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.
- Women who are pregnant (or who are considering pregnancy) or breastfeeding.
- Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class.
- Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
- Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant...
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
- Montgomery, Alabama, United States
- Phoenix, Arizona, United States
- Tucson, Arizona, United States
- Fountain Valley, California, United States
- Fremont, California, United States
- Huntington Beach, California, United States
- Irvine, California, United States
- Laguna Niguel, California, United States
- Los Angeles, California, United States
- Northridge, California, United States
- Oakland, California, United States
- Santa Monica, California, United States
- Sherman Oaks, California, United States
- Sunnyvale, California, United States
- Boca Raton, Florida, United States
- Coral Gables, Florida, United States
- Hialeah, Florida, United States
- Hollywood, Florida, United States
- Miami, Florida, United States
+ 223 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States; Montgomery, Alabama, United States; Phoenix, Arizona, United States; Tucson, Arizona, United States; Fountain Valley, California, United States; Fremont, California, United States and 237 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.